Children’s Therapeutics ScaleReady Partners with Industry Leaders to Support Seattle
Announces Children’s Therapeutics ScaleReady, in partnership with Wilson Wolf Manufacturing and Bio-Techne Corporation, has announced that Seattle Children’s Therapeutics, a division of the prestigious Seattle Children’s Research Institute, has been awarded a significant $125,000 G-Rex Grant. This prestigious grant will enable Seattle Children’s Therapeutics to integrate cutting-edge advancements into its CAR-T (chimeric antigen receptor T-cell) therapy platform using G-Rex bioreactors, further enhancing its capabilities in cell therapy development and manufacturing.
Christopher Brown, Announces the Director of GMP (Good Manufacturing Practice) Manufacturing at Seattle Children’s Therapeutics, expressed the importance of this technology in their CAR-T platform. “This technology has been a core component of our CAR-T platform for many years, and we have manufactured cell therapy products for hundreds of clinical trial participants using G-Rex bioreactors,” Brown said. The successful integration of G-Rex bioreactors into their manufacturing process has enabled Seattle Children’s Therapeutics to scale up the production of cellular therapies, providing hope to countless cancer patients through innovative treatments.
Seattle Children’s Therapeutics is Announces recognized as one of the early adopters of G-Rex technology, an innovative product developed by Wilson Wolf Manufacturing. The integration of G-Rex technology into their manufacturing processes has been crucial in helping the team streamline and scale their CAR-T therapy production. “Seattle Children’s was an early adopter of G-Rex and is comprised of world-class scientists, physicians, and engineers who bring hope to cancer patients,” stated John Wilson, CEO of Wilson Wolf and co-inventor of G-Rex. He expressed his enthusiasm about Seattle Children’s continued engagement with G-Rex technology, noting that the institution’s use of the G-Rex Grant Program will help simplify the manufacturing process of their groundbreaking cell therapies.
Seattle Children’s Therapeutics: A Pioneer in CAR-T Cell Therapy
As part of the $125,000 G-Rex Grant, Seattle Children’s Therapeutics Announces will have the opportunity to explore the full suite of G-Rex bioreactors, including fully closed systems that will be key in enhancing the efficiency and scalability of cell therapy production. Additionally, the grant will enable Seattle Children’s Therapeutics to work with a wide variety of GMP-grade cytokines supplied by Bio-Techne, which are critical in optimizing the manufacturing process for future CAR-T and other clinical trials. Cytokines are signaling proteins that play an important role in immune cell development and function, and their GMP-grade formulation is essential for maintaining the highest standards of quality in cell therapy manufacturing.
Announces One of the most exciting components of the G-Rex Grant is the opportunity for Seattle Children’s Therapeutics to gain early access to the product development pipeline for G-Rex. This will allow the institution to be among the first to evaluate and test new G-Rex devices and technologies that are still in development. This includes evaluating G-Rex’s advanced cell separation technology, which enables the isolation of T-cells within the G-Rex bioreactor without the need for expensive, complex instrumentation. The ability to perform these separations efficiently and cost-effectively is a major step forward in making cell therapies more accessible and scalable for widespread clinical application.
The G-Rex Grant Program Announces, a $20 million initiative from ScaleReady, aims to propel the development and manufacturing of cell and gene-modified therapies (CGT). Through this program, ScaleReady intends to support innovators in the field of cell therapy by awarding grant funds of up to $300,000. Recipients of the G-Rex Grant also benefit from exclusive support from ScaleReady’s growing consortium of partners, which includes top-tier experts and companies specializing in various aspects of cell therapy manufacturing and development.
The G-Rex Grant program Announces not only provides financial assistance but also offers recipients access to a wealth of resources and expertise. This includes specialized support in areas such as cGMP (current Good Manufacturing Practices) manufacturing, quality assurance, regulatory affairs, and CGT business operations. Additionally, grantees can tap into the collective knowledge of ScaleReady’s partners, who are leaders in developing and manufacturing technologies essential for cell therapy success.
This partnership and the awarding of the Announces G-Rex Grant to Seattle Children’s Therapeutics highlights the growing trend of collaboration within the biopharmaceutical and cell therapy industries, as stakeholders from across the sector come together to drive innovation and improve patient outcomes. The integration of G-Rex technology with Seattle Children’s cutting-edge therapies is a testament to the importance of ongoing research and development in the fight against cancer and other diseases that may benefit from advanced immunotherapies like CAR-T.
The Announces G-Rex bioreactor technology developed by Wilson Wolf Manufacturing is designed to improve the scalability and efficiency of cell therapy production. Unlike traditional open systems, G-Rex bioreactors are fully closed, reducing the risk of contamination and enhancing the consistency of cell culture conditions. This makes G-Rex an invaluable tool for institutions like Seattle Children’s Therapeutics that are looking to streamline their manufacturing processes while maintaining the highest standards of quality and safety.
Announces The future of cell and gene therapy relies on the development of scalable, efficient, and cost-effective manufacturing technologies. The collaboration between ScaleReady, Wilson Wolf, Bio-Techne, and Seattle Children’s Therapeutics is a significant step forward in achieving these goals. As more clinical trials move toward larger-scale production of cell therapies, the importance of advanced technologies like G-Rex cannot be overstated. The ability to produce high-quality cellular therapies at scale is essential to meeting the growing demand for these cutting-edge treatments and ensuring they are accessible to a broad range of patients.
For Announces Seattle Children’s Therapeutics, this grant and the associated support will play a pivotal role in advancing its CAR-T therapy platform. By enhancing their manufacturing capabilities with G-Rex technology and accessing the extensive expertise provided by ScaleReady’s network of partners, Seattle Children’s is well-positioned to continue developing innovative therapies that could have a profound impact on the treatment of pediatric cancers and other serious diseases.
As the biopharmaceutical industry continues to evolve, initiatives like the G-Rex Grant Program will be crucial in supporting the next generation of cell therapy innovators. The collaborative nature of the program fosters the development of new technologies and approaches that could lead to the next breakthroughs in medicine. With its focus on improving the manufacturing process for CAR-T and other cell-based therapies, the G-Rex Grant is an important step toward making life-saving therapies more accessible to patients around the world.
In conclusion, the awarding of the $125,000 G-Rex Grant to Seattle Children’s Therapeutics is a significant milestone for both the institution and the broader field of cell therapy. Through this collaboration, Seattle Children’s will be able to enhance its CAR-T platform, making it more efficient and scalable while benefiting from the expertise of ScaleReady, Wilson Wolf, and Bio-Techne. This partnership represents a shared commitment to advancing the state of cell therapy manufacturing, ultimately bringing innovative treatments to more patients and offering hope for those battling cancer and other serious conditions.
